文献速递血液透析通路

开放与血管内透析通路介入的Medicare报销区域与专科趋势

Regional and specialty-specific Medicare reimbursement trends in open and endovascular dialysis access interventions.
PubMed 文献 · J Vasc Surg · 2026-06-10

研究分析2019至2023年Medicare Part B中开放与血管内透析通路介入的报销趋势,按地区与专科分层。

要点

  • 设施场所开放与血管内透析通路介入报销在所有地区下降。
  • 非设施场所血管内介入报销平均下降27%,区域8和10降幅最大。
  • 各专科(血管外科、放射科、肾内科等)报销降幅无显著差异。

核心结论

  • 2019至2023年Medicare Part B透析通路介入报销持续下降,不受医生专科影响。
  • 部分区域报销降幅更大,开放设施手术以区域7和3最明显,非设施血管内介入以区域8和10最明显。

研究设计与样本

  • 查询2019-2023年Medicare医师与其他从业者按提供者和服务数据集,纳入开放与血管内透析通路介入。
  • 计算加权平均报销额,按实践场所、CMS区域和医生专科分层,金额调整至2023年美元。

主要发现

  • 设施场所开放手术报销降幅最大为区域7(-30%)和区域3(-24%)。
  • 设施场所血管内手术所有区域报销下降范围-20%至-29%。
  • 非设施场所平均报销下降27%,区域8降46%、区域10降40%。
  • 设施场所平均报销下降27.3%;头静脉转位降22%,贵要静脉转位降18%。
  • 设施血管内诊断性瘘管造影、血管成形、支架和血栓切除报销降20%至22%;非设施中心静脉血管成形降32%,外周透析支架降33%。

临床怎么用

  • 血管外科医生需了解透析通路介入报销在全国及区域层面持续下降的趋势。
  • 区域报销差异可能影响透析通路服务的提供与资源分配。

局限性

  • 仅分析Medicare Part B报销数据,未涵盖其他支付方。
  • 非设施分析仅纳入血管内手术,开放手术非设施数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Medicare Part B reimbursements continue to decline annually at the national level. The majority of dialysis patients qualify for Medicare regardless of their age. The objective of this study was to characterize Medicare reimbursement trends for open and endovascular dialysis access interventions stratified based on the geographic region and physician specialty. METHODS: The 2019-2023 Medicare Physician and Other Practitioners by Provider and Service data set was queried for open and endovascular procedures, including arteriovenous fistula or graft creations and endovascular maintenance/interventions. Weighted mean reimbursements were calculated. The data were stratified by practice setting (facility vs nonfacility), Centers for Medicare and Medicaid Services region, and physician specialty. All nonfacility analyses included only endovascular procedures. For open procedures, percentage changes in reimbursements were compared between vascular surgery and transplant/general surgery. For endovascular procedures, comparisons were made among vascular surgery, radiology, and nephrology. All monetary values were adjusted to the 2023 US dollars. RESULTS: In facility settings, the reimbursements declined across all regions. For open procedures, regions 7 (Central) and 3 (Mid-Atlantic) demonstrated the largest declines at -30% and -24%, respectively. For endovascular procedures, all regions showed similar decreases in reimbursement, ranging from -20% to -29%. In nonfacility locations, the average reimbursement declined in every region, with regions 8 (Mountain West) and 10 (Pacific Northwest) having the largest decreases at -46% and -40%, respectively. Facility reimbursements decreased by an average of -27.3%. Cephalic vein transposition (-22%) and basilic vein transposition (-18%) had the largest decreases with regard to open procedures. Facility-based endovascular procedures, including diagnostic fistulagram, angioplasty, stenting, and thrombectomy, demonstrated similar decreases in reimbursement, ranging from -20% to -22%. In nonfacility settings, the average reimbursement declined by -27%, with central venous angioplasty (-32%) and peripheral dialysis stent (-33%) having the largest declines. Overall, all specialties experienced a similar decrease in reimbursements for both open (P = .12) and endovascular (P = .35) interventions. CONCLUSIONS: Our analysis of dialysis access procedures billed to Medicare Part B from 2019 to 2023 demonstrated a continued decline in reimbursements regardless of physician specialty. Regional reimbursement patterns demonstrate decreased reimbursements across the board, with certain regions being disproportionately affected, including regions 7 (Central) and 3 (Mid-Atlantic) for open facility procedures and regions 8 (Mountain West) and 10 (Pacific Northwest) for endovascular nonfacility interventions.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Koh DJ, Tao B, Farber A, et al. Regional and specialty-specific Medicare reimbursement trends in open and endovascular dialysis access interventions. J Vasc Surg. 2026. PMID: 42269703. doi:10.1016/j.jvs.2026.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。